BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
ALAMEDA, Calif. & MENLO PARK, Calif.--BioTime, Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"), has raised $12.5 million through the sale of ...
ESI-014 and ESI-017 approved for use in Federally funded research ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the ...
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ...
Business complements firm’s existing cancer and stem cell research products subsidiaries. BioTime has set up a subsidiary OrthoCyte to focus on the development of novel stem cell-based regenerative ...
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Off
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research "The ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously ...
LifeMap Sciences' discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback